Tuebingen 2025

Precision Medicine and Diversity in PD: Lessons from the GEoPD and the path ahead

Join us in 2025 in Tuebingen as we mark the 20th anniversary of the Genetic Epidemiology of Parkinson’s disease (GEoPD). We will discuss how individualized strategies can embrace patient variability and drive more effective treatments.

For two decades, GEoPD’s global outreach has united clinicians, geneticists, data scientists, and other experts across 60 sites in 30 countries. This inclusive network fosters open collaboration, sharing region-specific insights and expanding our collective ability to identify genetic variations and novel therapeutic targets. Everyone’s contribution strengthens the mission to transform PD care.

Over the years, our decentralized and democratic model has safeguarded continuity and nurtured fresh leadership. Building on a shared repository of 41,988 PD cases and 41,505 control subjects, we have created a robust infrastructure for research breakthroughs. Key achievements include:

  • Establishing standardized protocols and data-sharing practices
  • Accelerating discovery of genetic risk factors and biomarkers
  • Fostering a global community of dedicated PD researchers

Program: Day 1



11th June


15.00


Tuebingen Tour for the participants
18:00Welcome drinks
19:00Steering committee dinner


12th June


08:00‑08:45


Registration
08:45‑09:00Welcome


Session 1


09:00‑10:30


Genomics and Epidemiology
Sonja ScholzUSA09:00‑09:30Leveraging genomics to advance precision medicine: lessons from Lewy body dementia
Alexis ElbazFrance09:30‑10:00Strengthening causal inference in Parkinson's disease research: triangulation of evidence"
Huw MorrisUK10:00‑10:30Genotype-Phenotype analysis
10:30‑11:00Coffee/Tea Break


Session 2


11:00‑12:30


Biomarkers and PD
Brit MollenhauerGermany11:00‑11:30Biomarker for Parkinson‘s disease to support prevention trials
Nicolas CuenaSpain11:30‑12:00From Eye to Brain: The Retina as a early Parkinson’s Disease Biomarker
Günther HöglingerGermany12:00‑12:30Biomarker-based diagnosis of PD. Where do we stand?
12:30‑14:00Lunch/Poster


Session 3


14:00‑15:30


DBS and PD
Andreas HornUSA14:00‑14:30Causal Mapping: From Connectomic Deep Brain Stimulation toward the 'Human Dysfunctome'
Aikaterini MarkopoulouUSA14:30‑15:00STN DBS, disease etiology and progression: what is the connection
Jens VolkmannGermany15:00‑15:30Can deep brain stimulation modify the course of Parkinson’s disease
15:30‑16:00Coffee/Tea Break


Session 4


16:00‑17:30


Mechanisms and Therapeutics
Claudio FranceschiItaly16:00‑16:30Brain/Peripheral Inflammaging and Parkinson's Disease
Shohreh Issazadeh-NavikasDenmark16:30‑17:00Damaged mitochondrial DNA as a result of immune disturbances can spread Parkinson’s Disease Dementia
Dario AlessioUK17:00‑17:30Regulation and Function of the LRRK2 Pathway
19:00Gala Dinner

Program: Day 2



Session 5


08:30‑11:00


GEoPD and Diversity
John IoannidisUSA08:30‑09:00Genetics, genomics, and precision medicine: towards making an impact"
Wael MohamadEgypt/Malaysia09:00‑09:30AfrAbia PD Genomic Consortium: The alternative to despair is to build an ark
Morenikeji KomolafeNigeria09:30‑10:00Sleep Disturbances  in  Patients with Parkinson's Disease in Ile-Ife, South Western Nige
Marieke DekkerTanzania10:00‑10:30A bird's eye on Parkinson's and Genetics in East Africa
Sun Ju ChungSouth Korea10:30‑11:00Mitochondrial DNA copy number as a potential biomarker for Parkinson’s disease: Whole genome sequencing study
11:00‑11:30Coffee/Tea Break


Session 6


11:30‑13:00


Patients world vs scientific world: Hope, challenges and the path ahead
Eduardo TolossaSpain11:30‑12:00Biomarker based diagnosis of Parkinson disease
Dennis DicksonUSA12:00‑12:30Neuropathology of parkinsonian syndromes
Zbigniew WszolekUSA12:30‑13:00CSF1R-Related Disorder
13:00‑14:00Lunch


Session 7


14:00‑16:30


Data blitz/GEoPD outreach
16.30‑17:00Break


Session 8


17:00‑18:30


PD funding and patients (converging interests or widening gap)
Frédéric DestrebecqBelgium17:00‑17:30Rethinking the care pathway for people with PD and closing the treatment gap – meeting patients’ needs and yielding economic benefits
Amelia HurseyUK17:30‑18:00Parkinson's Europe, connecting the voice of the Parkinson's community in Europe and sharing it globally.
Brian FiskeUSA18:00‑18:30MJFF’s Strategic Research Agenda and Current Priorities


Concluding remarks

We truly appreciate your support in advancing PD research outreach and developing more effective treatment strategies.

Endorsement and Sponsors

MDS_logo
KonP UKT 1